Oral fusidic acid for the treatment of mild-to-moderate hidradenitis suppurativa.
antibiotics
fusidic acid
hidradenitis suppurativa
therapeutic studies
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
03 Mar 2024
03 Mar 2024
Historique:
revised:
11
02
2024
received:
23
05
2023
accepted:
15
02
2024
medline:
4
3
2024
pubmed:
4
3
2024
entrez:
3
3
2024
Statut:
aheadofprint
Résumé
Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease. Tetracyclines are one of the few therapeutic options recommended for mild-to-moderate disease. This study aimed to investigate the efficacy of systemic fusidic acid's (FA) effectiveness in treating HS. This retrospective study analyzed 55 FA therapy cycles (TC, average weekly dose: 6409 mg; range: 5250-9800 mg; 2-12 weeks) in 49 patients. The outcome was evaluated using the Physician's Global Assessment (PGA) scale. Therapy response was defined as any reduction of inflammatory activity without the occurrence of flares. We also characterized adverse events and investigated predictors for treatment success. Results were compared to a matched control group receiving doxycycline. FA treatment (55 treatment cycles (TC); male: 45.5%; female: 54.5%) showed an overall response rate of 70.9% (39 TC). No worsening was observed. Significantly higher response rates were observed in females (83.3%, P = 0.026) and Hurley I (90.9%, P = 0.008). After multivariate adjustment, higher response rates were associated with the Hurley grade (P = 0.046) but not with gender (P = 0.0174). Adverse reactions (21.8% gastrointestinal symptoms) occurred in 27.3% (15 TC) and 46.7% within the first 4 weeks. Similar results were observed in the doxycycline control group (overall response rate: 76.4%). Oral FA is safe and improves symptoms in most patients. HS patients could benefit from oral FA treatment, especially in case of contraindications or resistance to tetracyclines.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease. Tetracyclines are one of the few therapeutic options recommended for mild-to-moderate disease. This study aimed to investigate the efficacy of systemic fusidic acid's (FA) effectiveness in treating HS.
METHODS
METHODS
This retrospective study analyzed 55 FA therapy cycles (TC, average weekly dose: 6409 mg; range: 5250-9800 mg; 2-12 weeks) in 49 patients. The outcome was evaluated using the Physician's Global Assessment (PGA) scale. Therapy response was defined as any reduction of inflammatory activity without the occurrence of flares. We also characterized adverse events and investigated predictors for treatment success. Results were compared to a matched control group receiving doxycycline.
RESULTS
RESULTS
FA treatment (55 treatment cycles (TC); male: 45.5%; female: 54.5%) showed an overall response rate of 70.9% (39 TC). No worsening was observed. Significantly higher response rates were observed in females (83.3%, P = 0.026) and Hurley I (90.9%, P = 0.008). After multivariate adjustment, higher response rates were associated with the Hurley grade (P = 0.046) but not with gender (P = 0.0174). Adverse reactions (21.8% gastrointestinal symptoms) occurred in 27.3% (15 TC) and 46.7% within the first 4 weeks. Similar results were observed in the doxycycline control group (overall response rate: 76.4%).
CONCLUSION
CONCLUSIONS
Oral FA is safe and improves symptoms in most patients. HS patients could benefit from oral FA treatment, especially in case of contraindications or resistance to tetracyclines.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 the International Society of Dermatology.
Références
Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16:61-65. https://doi.org/10.1007/s40257-014-0105-5
Janse IC, Deckers IE, van der Maten AD, Evers AW, Boer J, Van Der Zee HH, et al. Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol. 2017;176:1042-1047. https://doi.org/10.1111/bjd.14975
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82:1045-1058. https://doi.org/10.1016/j.jaad.2019.08.090
Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): retrospective analysis of 74 patients. J Am Acad Dermatol. 2017;77:123-129.e125. https://doi.org/10.1016/j.jaad.2017.01.055
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81:91-101. https://doi.org/10.1016/j.jaad.2019.02.068
Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180:1009-1017. https://doi.org/10.1111/bjd.17537
van Straalen KR, Tzellos T, Guillem P, Benhadou F, Cuenca-Barrales C, Daxhelet M, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol. 2021;85:369-378. https://doi.org/10.1016/j.jaad.2020.12.089
van der Zee HH, van de Bunte M, van Straalen KR. Management of mild hidradenitis suppurativa: our greatest challenge yet. Br J Dermatol. 2022;186:355-356. https://doi.org/10.1111/bjd.20780
Bettoli V, Manfredini M, Massoli L, Carillo C, Barozzi A, Amendolagine G, et al. Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol. 2019;33:930-936. https://doi.org/10.1111/jdv.15332
Schofer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20:6-15. https://doi.org/10.1684/ejd.2010.0833
Wark KJL, Cains GD. The microbiome in hidradenitis suppurativa: a review. Dermatol Ther (Heidelb). 2021;11:39-52. https://doi.org/10.1007/s13555-020-00465-w
Caposiena Caro RD, Molinelli E, Brisigotti V, Offidani A, Bianchi L. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation. Clin Exp Dermatol. 2021;46:96-102. https://doi.org/10.1111/ced.14388
Vural S, Gundogdu M, Akay BN, Boyvat A, Erdem C, Koçyiğit P, et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy. Dermatol Ther. 2019;32:e13003. https://doi.org/10.1111/dth.13003
Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol. 2016;41:852-857. https://doi.org/10.1111/ced.12933
Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619-644. https://doi.org/10.1111/jdv.12966
Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol. 1998;139(Suppl 53):37-40. https://doi.org/10.1046/j.1365-2133.1998.1390s3037.x
Moorhouse E, Fenelon L, Hone R, Smyth E, McGahon J, Dillon M. Staphylococcus aureus sensitivity to various antibiotics-a national survey in Ireland 1993. Ir J Med Sci. 1996;165:40-43. https://doi.org/10.1007/BF02942801
Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol. 1999;140:90-95. https://doi.org/10.1046/j.1365-2133.1999.02613.x
Ring HC, Bay L, Nilsson M, Kallenbach K, Miller IM, Saunte DM, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol. 2017;176:993-1000. https://doi.org/10.1111/bjd.15007
Hessam S, Sand M, Georgas D, Anders A, Bechara FG. Microbial profile and antimicrobial susceptibility of bacteria found in inflammatory hidradenitis suppurativa lesions. Skin Pharmacol Physiol. 2016;29:161-167. https://doi.org/10.1159/000446812
Christiansen K. Fusidic acid non-antibacterial activity. Int J Antimicrob Agents. 1999;12(Suppl 2):S73-S78. https://doi.org/10.1016/s0924-8579(98)00076-4
Jorgensen AR, Yao Y, Thomsen SF, Ring HC. Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. Int J Dermatol. 2021;60:785-791. https://doi.org/10.1111/ijd.15459
Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219:148-154. https://doi.org/10.1159/000228334
van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143-147. https://doi.org/10.1159/000228337
Wiala A, Ranjan R, Schnidar H, Rappersberger K, Posch C. Automated classification of hidradenitis suppurativa disease severity by convolutional neural network analyses using calibrated clinical images. J Eur Acad Dermatol Venereol. 2024;38:576-582.https://doi.org/10.1111/jdv.19639